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Of 3,532 participants, 735 participants were excluded due to the following reasons: missing 
biomarker measurements (n=82), prevalent heart failure (n=38), left ventricular (LV) systolic 
dysfunction (LV fractional shortening <0.30, or mild or greater LV systolic dysfunction by 
visual assessment on echocardiography) (n=302), missing covariates (n=60), or missing 
genotype (n=253). 
 
Clinical Assessment  
Diabetes mellitus was defined as a fasting glucose ≥126 mg/dL, non-fasting blood glucose ≥200 
mg/dL, or the use of insulin or oral hypoglycemic medications.  LV hypertrophy was defined 
using previously reported ECG criteria (1).  Estimated glomerular filtration rate (eGFR) was 
calculated using the Modification of Diet in Renal Disease equation (2).  High-sensitivity CRP 
and B-type natriuretic peptide (BNP) were measured as previously described (3).  Total and 
high-density lipoprotein cholesterol were measured by standard enzymatic methods using an 
Abbott Diagnostics ABA-200 analyzer (4).    
 
Expression SNP analysis 
We identified alias rsIDs (n=10) for significant sST2 loci using SNAP (5).  Further proxy SNPs 
in high linkage disequilibrium (r2>0.9) were identified with SNAP.  Current and alias rsIDs were 
searched for primary SNPs and LD proxies against a collected database of expression SNP 
(eSNP) results including the following tissues: fresh lymphocytes (6), fresh leukocytes (7), 
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leukocyte samples in individuals with Celiac disease (8), lymphoblastoid cell lines (LCL) 
derived from asthmatic children (9), HapMap LCL from 3 populations (10), a separate study on 
HapMap CEU LCL (11), peripheral blood monocytes (12, 13), omental and subcutaneous 
adipose (14, 15), stomach (15), and whole blood samples (16), endometrial carcinomas (17), 
brain cortex(12, 18), 3 large studies of brain regions including prefrontal cortex, visual cortex 
and cerebellum, respectively (Emilsson, personal communication), liver (15, 19, 20), osteoblasts 
(21), skin (22), and additional fibroblast, T cell and LCL samples (23).  The collected eSNP 
results met criteria for statistical significance for association with gene transcript levels as 
described in the original papers. 
 
Cell Culture Studies 
Cell Culture And Reagents 
Human KU812, a basophil cell line, was kindly provided by Dr. David Frank (Dana-Faber 
Cancer Institute, Boston, MA) and maintained in RPMI 1640 (Invitrogen) containing 10% FBS. 
HEK293 cells were cultured in DMEM (Invitrogen) containing 10% FBS.  IL-33 (Peprotech), 
anti-ST2 mAb (R&D), PD98059 (Invivogen), SP600125 (Invivogen), Rapamycin (Invivogen), 
wortmannin (Invivogen), Bay11-7082 (Invivogen), SR 11302 (Tocris Bioscience), Phorbol 12-
myristate 13-acetate (PMA, Sigma Aldrich) were commercially available and were used in this 
study. 
 
Cloning And Plasmids 
Full-length wild type human ST2L was obtained via Reverse Transcription-PCR from KU812 
cells cDNA by using forward primer (5'-CTGGAGTAATCTCAACAACG-3') and reverse 
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primer (5'-CGAGTTACCAATACTTGCTC-3').  pCR-Blunt II Topo vector (Invitrogen) was 
used as intermediate vector.  Mutations were introduced by using PCR-based mutagenesis.  Full-
length ST2L cDNA were then subcloned into pCDH-EF1-MCS-T2A-Puro lentiviral vector 
(System Biosciences) by using the forward primer (5'-
AGCGCTAGCATGGGGTTTTGGATCTTAGC- 3') and the reverse primer containing a His-taq 
before the stop codon (5'-GCTGGATCCCTAATGATGATGATGATGATGTTGCTTCT 
GGGCAGCCAAG-3') for cell line creation.  All constructs were verified by DNA sequencing. 
 
Lentivirus Preparation And Cell Line Creation 
Lentiviral constructs were introduced with psPAX and pMD2.G packaging and envelope vectors 
into 293TN cells using PureFection reagent per manufacturer's protocol as previous described 
(24).  72 h later, culture media were harvested and lentiviral particles concentrated by 
ultracentrifugation (if destined for in vivo delivery) or Peg-IT reagent (if destined for cell line 
creation).  Stable cell lines were created by transducing KU812 cells with concentrated lentivirus 
and subjected to subsequent puromycin selection.  Expression was confirmed via Western 
blotting for ST2 and/or His-taq as appropriate. Membrane and cytosol fractions of the cell lysates 
were prepared by using Mem-PER Eukaryotic Membrane Protein Extraction Reagent Kit 
(Thermal Scientific) according to manufacturer’s instruction. 
 
ST2 Promoter Constructs And Promoter Assay 
We used PCR with specific primers to amplify the different regions upstream of exon 1a (distal) 
and exon 1b (proximal) of the human IL1RL1 gene from the DNA of the BAC clone (RP11-
315O22).  ST2 proximal and distal promoters fragments containing different lengths of 
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sequences were inserted between the SacI and NheI sites of the pGL3-basic vector (Promega) 
containing the entire coding sequences of firefly luciferase with specific primers.  
 
The distal promoter fragments were constructed by using the primers:  
hST2-exon1a/-697F: 5'-ATCGGGATCCGAGCTCAGATAGGCCATCTCGGGCAT-3' 
hST2-exon1a/+741R: 5'-ATATGCTAGCACCAAAACACAATTAAACTCCT-3' 
The proximal promoter fragments were constructed by using the primers: 
hST2-exon1b/-1745F: 5'-ATCGGGATCCGAGCTC TGTAAATCACTTAGACTGTG-3' 
hST2-exon1b/+200R: 5'-ATATGCTAGCTGCTGTGGAATACATGAGAA-3' 
 
For reporter assay, KU812 cells expressing ST2L variants were plated in 12-well plates (1 x 106 
cells/well, n=6 per treatments) and maintained in RPMI serum free medium before transfection.  
Cells were transfected by using the Purefection (System Biosciences) with 500 ng of reporter 
plasmids.  All cells were also transfected with a SEAP control plasmid for normalizing 
transfection efficiencies.  After transfection, cells were maintained in RPMI serum free medium 
overnight (18 h).  For signal inhibitor treatment study, cells were incubated with signal inhibitors 
for additional 24 h. After 24 h incubation, cells were harvested in lysis buffer and assayed for 
luciferase activity per the manufacturer’s protocol.  
 
Realtime-PCR 
Total RNA was isolated using Trizol reagent per manufacturer’s instructions (Invitrogen).  
cDNA was synthesized from 1 µg of total RNA and random hexamers using the TaqMan 
Reverse Transcription kit (Applied Biosystems).  1 µl diluted cDNA was used per 20 µl reaction 
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from an initial input of 1 µg total RNA diluted to a final volume of 600 µl following cDNA 
reverse transcription.  Real time PCR was performed in a 7300 Realtime PCR system (Applied 
Biosystems), with 40 cycles of: 95°C x 15 sec, 60°C x 1 min.  All reactions were performed in 
duplicate.  Relative amount of sST2 or ST2L mRNA was normalized to HPRT. 
The following primers specific for sST2, ST2L, and HPRT were used in this study: 
hST2-RT (CDS)-F: 5'-CTGTCTGGCCCTGAATTTGC-3’; 










hHPRT-R436: 5'-AATTACTTTTATGTCCCCTGTTGACTGG -3’; 
 
For the qRT-PCR analysis of sST2 mRNA expression, KU812 cells (1 x 106/well, n=2 per 
treatments) were treated with DMSO or IL-33 (20ng/ml) with and without signal inhibitors as 
indicated.  Cells were pretreated with Wortmannin (5µM), LY294002 (5µM), Rapamycin 
(5µM), PD98059 (10 µM), SP60125 (10 µM), BAY11-7082 (10 µM), or SR11302 (10 µM) for 
30 minutes, and then incubated with IL-33 (20 ng/ml) for 8 h.  RNA was then isolated for qRT 
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PCR analysis.  For anti-ST2 mAb inhibition experiments, cells were pre-incubated with PBS, 
Rapamycin (5mM), anti-ST2 mAb (1µg/ml), IL-33 (20 ng/ml), IL-33 (20 ng/ml) plus anti-ST2 
(1µg/ml), IL-33 (20 ng/ml) plus Rapamycin (5µM), IL-33 (20 ng/ml) plus Rapamycin (1µg/ml) 
plus anti-ST2 mAb (1µg/ml) or Rapamycin (1µg/ml) plus anti-ST2 (1µg/ml).  Cells were treated 
for 8 h for qRT-PCR analysis, and 24 h for ELISA analysis. 
 
ELISA 
For basal sST2 protein expression level analysis, KU812, U937, Jurkat T, or A549  cells (1 x 
106/well, n=3 per treatments) expressing wild type (WT) or IL1RL1 variants (A78E, A433T, 
Q501K, Q501R, T549I, L551S) are cultured in serum free RPMI 1640 medium for 24 h.  The 
media were collected for ELISA analysis for sST2 (PresageTM ST2; Critical Diagnostics, San 
Diego, CA, USA), IL-1β (R&D System), and IL-33 (R&D System).  For signal activation 
analysis, cells were subjected to serum starvation for 8 h, then treated with PBS or IL-33 for 
30min.  Cell lysates were then used for ELISA detection of phospho-NF-κB p65 (Ser536), 
phospho-c-Jun (Ser63), phospho-AKT (Thr308), and phospho-STAT3 (Tyr705) according to 
manufacturer’s instructions (Cell Signal). 
  
Co-Immunoprecipitation 
HEK293 cells expressing IL1RL1 variants were plated in 6-well plates (1 x 106 cells/well, n=6 
per treatments) and maintained in DMEM serum free medium before transfection.  Cells were 
transfected by using the Purefection (System Biosciences) with 500 ng of pcDNA3.1-PI3K-
p85alpha-FLAG (kindly provided by Dr. Umut Ozcan, Children’s Hospital Boston), pCDNA3.1-
Mal-c-myc, and pcDNA3.1-MYD88-HA (kindly provided by Prof. Alexander N. R. Weber, 
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German Cancer Research Centre (DKFZ), Germany. After 24 hour transfection, the cells were 
harvested and lysates were immunoprecipitated by anti-FLAG for PI3K-p85 subunit, anti-c-myc 
for Mal, anti-HA for MYD88,  or anti-His for ST2L variant protein.  Precipitates and whole cell 




Clinical Correlates of sST2 concentrations 
Age and sex were forced into the model; eligible covariates included systolic blood pressure, 
diabetes mellitus, body mass index, cigarette smoking, total and high-density lipoprotein 
cholesterol, hypertension treatment, LV hypertrophy, atrial fibrillation, and eGFR.   
 
Heritability 
In secondary analyses, we adjusted for duration of hypertension and diabetes, defined as the time 
from earliest study visit when diagnosis was confirmed to the sixth examination cycle.  We 
further adjusted for potential inflammatory conditions, including the current use of 
glucocorticoids, history of asthma or use of bronchodilators, cardiovascular disease, self-reported 
history of cancer or tumor, C-reactive protein concentration, and the use of non-steroidal anti-
inflammatory medications. 
 
Cell Culture Studies 
All data are expressed as means ± s.e.  For two sample comparisons, a two-tailed t test was 
employed.  P values less than 0.05 were considered significant. 
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Supplemental Table 1. Characteristics of 2,991 participants  
 Men (n=1,241) Women (n=1,556) 
Age, years 58 (10) 59 (10) 
Systolic blood pressure, mmHg 129 (17) 127 (20) 
Diastolic blood pressure, mmHg 78 (9) 74 (9) 
Body-mass index, kg/m2 28 (4) 27 (6) 
Diabetes mellitus, % 12 9 
Anti-hypertensive treatment, % 28 25 
Smoker, % 15 16 
Atrial fibrillation, % 2 1 
Left ventricular hypertrophy, % 1 0 
Total cholesterol, mg/dl 200 (40) 212 (38) 
HDL cholesterol, mg/dl 44 (12) 58 (16) 
eGFR, ml/min/1.73m2 91 (44) 89 (43) 
sST2, ng/ml, median (25%ile-75%ile) 23.4 (19.1-28.8) 18.7 (15.3-23.2) 
 
Values are mean (standard deviation) unless otherwise indicated. 
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Supplemental Table 2.  Genome-wide significant SNPs associated with sST2 concentrations 








MAF beta se P 
2 rs950880 102298994 IL1RL1 C A 0.39 -0.18 0.01 7.11E-94 
2 rs13001325 102305468 IL1RL1 C T 0.39 -0.18 0.01 8.64E-94 
2 rs12479210 102315593 IL1RL1 C T 0.39 -0.18 0.01 9.42E-94 
2 rs13019081 102317254 IL1RL1 A C 0.39 -0.18 0.01 9.47E-94 
2 rs1420101 102324148 IL1RL1 C T 0.39 -0.18 0.01 4.33E-92 
2 rs12712142 102327016 IL1RL1 C A 0.40 -0.17 0.01 1.68E-84 
2 rs6543119 102329504 IL1RL1 A T 0.40 -0.17 0.01 3.55E-84 
2 rs13017455 102331174 IL1RL1 C T 0.40 -0.17 0.01 6.92E-84 
2 rs11123923 102334276 IL1RL1 C A 0.40 -0.16 0.01 4.89E-81 
2 rs2287037 102345460 IL18R1 C T 0.40 -0.16 0.01 1.26E-80 
2 rs12998521 102340849 IL18R1 G T 0.40 -0.16 0.01 1.27E-80 
2 rs953934 102298725 IL1RL1 C T 0.56 -0.15 0.01 2.56E-70 
2 rs12712135 102297380 IL1RL1 A G 0.56 -0.15 0.01 2.70E-70 
2 rs11123918 102301669 IL1RL1 T C 0.55 -0.15 0.01 8.88E-68 
2 rs10182639 102302237 IL1RL1 C A 0.55 -0.15 0.01 8.99E-68 
2 rs11690443 102302563 IL1RL1 T A 0.55 -0.15 0.01 9.18E-68 
2 rs4142132 102303914 IL1RL1 G A 0.55 -0.15 0.01 9.43E-68 
2 rs974389 102303413 IL1RL1 G A 0.55 -0.15 0.01 9.44E-68 
2 rs11123920 102306265 IL1RL1 C T 0.55 -0.15 0.01 9.44E-68 
2 rs12996772 102313633 IL1RL1 A T 0.55 -0.15 0.01 9.44E-68 
2 rs6706844 102306844 IL1RL1 T C 0.55 -0.15 0.01 9.44E-68 
2 rs1420102 102315251 IL1RL1 C T 0.55 -0.15 0.01 9.44E-68 
2 rs12466380 102315371 IL1RL1 A G 0.55 -0.15 0.01 9.45E-68 
2 rs1420088 102305866 IL1RL1 T C 0.55 -0.15 0.01 9.45E-68 
2 rs10189711 102297313 IL1RL1 A G 0.55 -0.15 0.01 9.68E-68 
2 rs1558622 102296579 IL1RL1 G A 0.55 -0.15 0.01 9.75E-68 
2 rs4090473 102289419 IL1RL1 C G 0.55 -0.15 0.01 9.95E-68 
2 rs4399750 102284220 IL1RL1 T C 0.55 -0.15 0.01 1.04E-67 
2 rs1997467 102317505 IL1RL1 A G 0.55 -0.15 0.01 1.06E-67 
2 rs1997466 102317899 IL1RL1 C G 0.55 -0.15 0.01 1.21E-67 
2 rs1362350 102318230 IL1RL1 G C 0.55 -0.15 0.01 1.43E-67 
2 rs1362349 102318404 IL1RL1 G C 0.55 -0.15 0.01 9.54E-67 
2 rs12712141 102319499 IL1RL1 T C 0.55 -0.15 0.01 1.06E-66 
2 rs11685424 102293413 IL1RL1 G A 0.55 -0.15 0.01 4.15E-66 
2 rs12469506 102332303 IL1RL1 C T 0.30 -0.13 0.01 1.05E-41 
2 rs17026974 102318792 IL1RL1 G A 0.28 -0.13 0.01 3.26E-40 
2 rs873022 102322115 IL1RL1 G T 0.28 -0.13 0.01 5.40E-40 
2 rs3771177 102322292 IL1RL1 G T 0.28 -0.13 0.01 5.55E-40 
2 rs3732129 102323964 IL1RL1 T C 0.28 -0.13 0.01 6.35E-40 
2 rs12905 102326439 IL1RL1 G A 0.28 -0.13 0.01 1.04E-39 
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2 rs11694360 102427579 IL18RAP G A 0.35 -0.13 0.01 1.40E-39 
2 rs11123928 102427718 IL18RAP G A 0.35 -0.13 0.01 1.40E-39 
2 rs7597017 102428548 IL18RAP A G 0.35 -0.13 0.01 1.41E-39 
2 rs13029918 102323723 IL1RL1 A G 0.05 -0.29 0.02 1.54E-39 
2 rs11465730 102433290 IL18RAP A G 0.48 -0.12 0.01 5.13E-38 
2 rs6705385 102443001 IL18RAP A C 0.48 -0.12 0.01 6.48E-38 
2 rs6705498 102443102 IL18RAP A G 0.48 -0.12 0.01 6.52E-38 
2 rs6719196 102443320 IL18RAP G T 0.48 -0.12 0.01 6.59E-38 
2 rs3821204 102326713 IL1RL1 C G 0.28 -0.13 0.01 8.01E-38 
2 rs13024003 102274193 IL1RL1 G C 0.05 -0.29 0.02 1.17E-37 
2 rs13017541 102272608 IL1RL1 C T 0.05 -0.29 0.02 1.25E-37 
2 rs13407644 102271783 IL1RL1 A G 0.05 -0.29 0.02 1.97E-37 
2 rs13024772 102268605 IL1RL1 G A 0.05 -0.29 0.02 2.59E-37 
2 rs12463588 102451689 SLC9A4 C G 0.48 -0.11 0.01 3.21E-37 
2 rs2310302 102452481 SLC9A4 G C 0.48 -0.11 0.01 3.62E-37 
2 rs12469887 102453190 SLC9A4 T C 0.48 -0.11 0.01 4.08E-37 
2 rs12989419 102267186 IL1RL1 A C 0.05 -0.29 0.02 4.72E-37 
2 rs4140786 102454608 SLC9A4 G T 0.48 -0.11 0.01 5.70E-37 
2 rs10201184 102455510 SLC9A4 G C 0.48 -0.11 0.01 7.08E-37 
2 rs17027006 102331764 IL1RL1 G C 0.28 -0.12 0.01 1.36E-36 
2 rs1420103 102315064 IL1RL1 C A 0.23 0.13 0.01 1.01E-35 
2 rs2310220 102318283 IL1RL1 A G 0.23 0.13 0.01 1.13E-35 
2 rs3771172 102352244 IL18R1 C T 0.28 -0.12 0.01 1.27E-35 
2 rs3771171 102352382 IL18R1 T C 0.28 -0.12 0.01 1.28E-35 
2 rs2160202 102352586 IL18R1 G A 0.28 -0.12 0.01 1.29E-35 
2 rs4851005 102377984 IL18R1 C T 0.36 -0.11 0.01 2.30E-35 
2 rs2058622 102351856 IL18R1 G A 0.23 0.13 0.01 2.88E-35 
2 rs3771170 102352412 IL18R1 A T 0.23 0.13 0.01 2.91E-35 
2 rs2058623 102352602 IL18R1 T C 0.23 0.13 0.01 2.95E-35 
2 rs1465321 102353050 IL18R1 C T 0.23 0.13 0.01 3.03E-35 
2 rs2287034 102377020 IL18R1 C A 0.28 -0.12 0.01 2.22E-34 
2 rs3849365 102510823 SLC9A4 A G 0.37 0.11 0.01 2.61E-34 
2 rs13009757 102278606 IL1RL1 C T 0.05 -0.27 0.02 2.67E-34 
2 rs17027037 102361316 IL18R1 A G 0.28 -0.12 0.01 7.14E-34 
2 rs2080289 102361452 IL18R1 G A 0.28 -0.12 0.01 7.36E-34 
2 rs11683700 102363237 IL18R1 C T 0.28 -0.12 0.01 8.58E-34 
2 rs1035130 102367834 IL18R1 C T 0.28 -0.12 0.01 1.15E-33 
2 rs4851582 102417990 IL18RAP T C 0.28 -0.12 0.01 1.25E-33 
2 rs11681718 102417576 IL18RAP A G 0.28 -0.12 0.01 1.26E-33 
2 rs17027166 102421852 IL18RAP G A 0.28 -0.12 0.01 1.28E-33 
2 rs10490204 102422966 IL18RAP A C 0.28 -0.12 0.01 1.28E-33 
2 rs17027179 102423591 IL18RAP C T 0.28 -0.12 0.01 1.29E-33 
2 rs10490203 102425669 IL18RAP T G 0.28 -0.12 0.01 1.30E-33 
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2 rs3771150 102427283 IL18RAP G A 0.28 -0.12 0.01 1.31E-33 
2 rs4851570 102372819 IL18R1 A G 0.28 -0.12 0.01 1.44E-33 
2 rs1135354 102380734 IL18R1 T G 0.28 -0.12 0.01 1.93E-33 
2 rs1014286 102515532 SLC9A4 A G 0.35 0.11 0.01 2.61E-33 
2 rs2008159 102515594 SLC9A4 G A 0.35 0.11 0.01 2.61E-33 
2 rs2008157 102515614 SLC9A4 G A 0.35 0.11 0.01 2.61E-33 
2 rs741285 102514601 SLC9A4 T C 0.35 0.11 0.01 2.61E-33 
2 rs1005043 102511858 SLC9A4 G A 0.35 0.11 0.01 2.62E-33 
2 rs4851018 102513047 SLC9A4 T C 0.35 0.11 0.01 2.62E-33 
2 rs17027230 102445762 IL18RAP C T 0.28 -0.12 0.01 2.85E-33 
2 rs1005042 102511791 SLC9A4 G A 0.35 0.11 0.01 2.88E-33 
2 rs1829849 102516130 SLC9A4 C A 0.35 0.11 0.01 2.89E-33 
2 rs6737119 102517541 SLC9A4 A G 0.35 0.11 0.01 3.05E-33 
2 rs6709284 102517596 SLC9A4 G C 0.35 0.11 0.01 3.22E-33 
2 rs2177317 102517751 SLC9A4 G A 0.36 0.11 0.01 3.73E-33 
2 rs11693955 102395597 IL18RAP A T 0.28 -0.12 0.01 4.38E-33 
2 rs13015714 102338297 IL1RL1 T G 0.22 0.13 0.01 4.47E-33 
2 rs3771156 102403109 IL18RAP C T 0.28 -0.12 0.01 4.56E-33 
2 rs3849364 102510674 SLC9A4 C T 0.36 0.11 0.01 4.85E-33 
2 rs3732123 102384509 IL18R1 C G 0.28 -0.12 0.01 4.92E-33 
2 rs12712156 102510452 SLC9A4 C A 0.36 0.11 0.01 5.42E-33 
2 rs4851617 102518492 SLC9A4 T C 0.35 0.11 0.01 6.62E-33 
2 rs17027087 102382350 IL18R1 C T 0.28 -0.12 0.01 8.44E-33 
2 rs4241211 102509591 SLC9A4 G T 0.36 0.11 0.01 9.24E-33 
2 rs4851011 102456110 SLC9A4 C T 0.28 -0.12 0.01 1.23E-32 
2 rs17027255 102456559 SLC9A4 C T 0.28 -0.12 0.01 1.24E-32 
2 rs4292112 102520212 SLC9A4 A G 0.36 0.11 0.01 1.24E-32 
2 rs17027258 102457972 SLC9A4 A G 0.28 -0.12 0.01 1.31E-32 
2 rs2015478 102507879 SLC9A4 G A 0.36 0.11 0.01 1.35E-32 
2 rs1357471 102506904 SLC9A4 T C 0.36 0.11 0.01 2.02E-32 
2 rs4851614 102506830 SLC9A4 T C 0.36 0.11 0.01 2.49E-32 
2 rs10490202 102527264 SLC9A4 G C 0.36 0.11 0.01 5.15E-32 
2 rs1362347 102286017 IL1RL1 C T 0.11 -0.17 0.01 1.14E-31 
2 rs2270297 102359107 IL18R1 C T 0.22 0.12 0.01 1.45E-31 
2 rs12987782 102304398 IL1RL1 G A 0.11 -0.17 0.01 1.47E-31 
2 rs13001301 102305430 IL1RL1 C T 0.11 -0.17 0.01 1.49E-31 
2 rs6753717 102359593 IL18R1 C A 0.22 0.12 0.01 1.49E-31 
2 rs6750020 102361146 IL18R1 A G 0.22 0.12 0.01 1.51E-31 
2 rs3771179 102320324 IL1RL1 T G 0.11 -0.17 0.01 1.51E-31 
2 rs3755278 102318649 IL1RL1 T C 0.11 -0.17 0.01 1.52E-31 
2 rs13016771 102325512 IL1RL1 G A 0.11 -0.17 0.01 1.53E-31 
2 rs17695648 102314613 IL1RL1 A G 0.11 -0.17 0.01 1.59E-31 
2 rs2110734 102418638 IL18RAP T C 0.22 0.12 0.01 2.52E-31 
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2 rs6746271 102419427 IL18RAP C G 0.22 0.12 0.01 2.52E-31 
2 rs2058660 102420881 IL18RAP A G 0.22 0.12 0.01 2.52E-31 
2 rs2058658 102421235 IL18RAP C T 0.22 0.12 0.01 2.52E-31 
2 rs4851009 102422076 IL18RAP A G 0.22 0.12 0.01 2.53E-31 
2 rs1558650 102426456 IL18RAP A T 0.22 0.12 0.01 2.53E-31 
2 rs6734736 102429312 IL18RAP T C 0.22 0.12 0.01 2.53E-31 
2 rs6708413 102429801 IL18RAP A G 0.22 0.12 0.01 2.53E-31 
2 rs917996 102448705 SLC9A4 A C 0.22 0.12 0.01 2.91E-31 
2 rs6717915 102446051 SLC9A4 C A 0.22 0.12 0.01 2.92E-31 
2 rs6718157 102446246 SLC9A4 T A 0.22 0.12 0.01 2.92E-31 
2 rs6720564 102445729 IL18RAP C T 0.22 0.12 0.01 2.95E-31 
2 rs4241210 102445172 IL18RAP A G 0.22 0.12 0.01 2.97E-31 
2 rs2272128 102406361 IL18RAP A G 0.22 0.12 0.01 3.00E-31 
2 rs6543141 102442783 IL18RAP A G 0.22 0.12 0.01 3.06E-31 
2 rs6705001 102442642 IL18RAP G A 0.22 0.12 0.01 3.08E-31 
2 rs6761825 102441993 IL18RAP C T 0.22 0.12 0.01 3.11E-31 
2 rs1468791 102458453 SLC9A4 G A 0.22 0.12 0.01 3.11E-31 
2 rs4070554 102440925 IL18RAP G A 0.22 0.12 0.01 3.16E-31 
2 rs917997 102437000 IL18RAP C T 0.22 0.12 0.01 3.36E-31 
2 rs7559479 102435219 IL18RAP A G 0.22 0.12 0.01 3.42E-31 
2 rs3817465 102406016 IL18RAP T A 0.22 0.12 0.01 3.42E-31 
2 rs7597819 102459338 SLC9A4 G A 0.22 0.12 0.01 3.51E-31 
2 rs6737668 102459513 SLC9A4 T C 0.22 0.12 0.01 3.56E-31 
2 rs1420106 102401476 IL18RAP G A 0.22 0.12 0.01 4.04E-31 
2 rs3755268 102404959 IL18RAP G C 0.22 0.12 0.01 4.04E-31 
2 rs3755267 102405019 IL18RAP G T 0.22 0.12 0.01 4.04E-31 
2 rs1807782 102399579 IL18RAP T C 0.22 0.12 0.01 4.08E-31 
2 rs11694658 102411452 IL18RAP G A 0.22 0.12 0.01 4.18E-31 
2 rs2160232 102413312 IL18RAP A G 0.22 0.12 0.01 4.27E-31 
2 rs6716784 102414899 IL18RAP G T 0.22 0.12 0.01 4.42E-31 
2 rs6543134 102416890 IL18RAP G T 0.22 0.12 0.01 4.54E-31 
2 rs2041756 102416342 IL18RAP G A 0.22 0.12 0.01 4.54E-31 
2 rs2110735 102417357 IL18RAP G A 0.22 0.12 0.01 4.54E-31 
2 rs990171 102453202 SLC9A4 C A 0.22 0.12 0.01 5.02E-31 
2 rs4851575 102391635 IL18R1 A G 0.22 0.12 0.01 5.15E-31 
2 rs4851007 102391245 IL18R1 G T 0.22 0.12 0.01 5.63E-31 
2 rs1035127 102386351 IL18R1 G A 0.22 0.12 0.01 5.65E-31 
2 rs1921622 102332499 IL1RL1 A G 0.47 0.10 0.01 6.06E-31 
2 rs7581853 102534156 SLC9A4 T C 0.36 0.11 0.01 6.23E-31 
2 rs10193009 102535409 SLC9A4 T C 0.36 0.11 0.01 6.23E-31 
2 rs11123937 102536114 SLC9A4 A G 0.36 0.11 0.01 6.52E-31 
2 rs887971 102407599 IL18RAP T C 0.30 -0.11 0.01 7.00E-31 
2 rs12712159 102536414 SLC9A4 A G 0.36 0.11 0.01 7.02E-31 
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2 rs887972 102407377 IL18RAP G A 0.30 -0.11 0.01 7.31E-31 
2 rs997056 102537351 SLC9A4 G A 0.36 0.11 0.01 8.39E-31 
2 rs2110737 102538695 SLC9A4 A T 0.36 0.11 0.01 1.09E-30 
2 rs17639215 102319876 IL1RL1 G A 0.13 0.15 0.01 1.71E-30 
2 rs10210658 102542181 SLC9A4 G T 0.36 0.11 0.01 1.86E-30 
2 rs10469840 102459675 SLC9A4 C T 0.23 0.12 0.01 2.34E-29 
2 rs985523 102320808 IL1RL1 G A 0.13 0.14 0.01 6.56E-28 
2 rs6719130 102324668 IL1RL1 C T 0.13 0.14 0.01 1.07E-27 
2 rs12999542 102331824 IL1RL1 A C 0.11 -0.15 0.01 2.08E-27 
2 rs12996097 102330060 IL1RL1 G A 0.11 -0.15 0.01 2.17E-27 
2 rs13028993 102330381 IL1RL1 T C 0.11 -0.15 0.01 2.17E-27 
2 rs12989197 102329171 IL1RL1 G A 0.11 -0.15 0.01 2.20E-27 
2 rs1946131 102328361 IL1RL1 C T 0.11 -0.15 0.01 2.21E-27 
2 rs12999517 102325692 IL1RL1 T C 0.11 -0.15 0.01 3.12E-27 
2 rs10515921 102347450 IL18R1 T G 0.13 0.14 0.01 1.85E-25 
2 rs10208293 102332742 IL1RL1 G A 0.29 0.10 0.01 2.28E-24 
2 rs2241116 102369697 IL18R1 C A 0.22 -0.11 0.01 2.38E-24 
2 rs11465596 102353525 IL18R1 C A 0.13 0.14 0.01 2.70E-24 
2 rs951774 102279096 IL1RL1 C A 0.14 0.13 0.01 3.78E-24 
2 rs11465597 102353645 IL18R1 A G 0.11 -0.15 0.01 6.02E-24 
2 rs2293225 102402321 IL18RAP C T 0.22 -0.11 0.01 8.02E-24 
2 rs9308855 102257227 IL1RL2 G A 0.25 0.11 0.01 1.09E-23 
2 rs1882511 102250153 IL1RL2 A G 0.25 0.11 0.01 1.29E-23 
2 rs1922288 102254997 IL1RL2 C T 0.23 0.12 0.01 2.04E-23 
2 rs3771167 102352620 IL18R1 A G 0.12 0.14 0.01 6.07E-23 
2 rs6728945 102352903 IL18R1 T C 0.12 0.14 0.01 6.86E-23 
2 rs12469892 102262216 IL1RL1 G A 0.13 0.13 0.01 7.05E-23 
2 rs6747153 102270259 IL1RL1 G A 0.28 0.10 0.01 8.03E-23 
2 rs11690532 102442858 IL18RAP C T 0.19 -0.11 0.01 9.03E-23 
2 rs1882510 102250050 IL1RL2 C T 0.13 0.13 0.01 9.03E-23 
2 rs2192669 102617986 SLC9A2 C T 0.31 0.09 0.01 1.91E-22 
2 rs13015695 102254873 IL1RL2 C A 0.06 -0.20 0.02 2.17E-22 
2 rs12995644 102246459 IL1RL2 C A 0.06 -0.19 0.02 3.97E-22 
2 rs6724109 102491450 SLC9A4 G C 0.23 0.10 0.01 4.05E-22 
2 rs6751949 102491570 SLC9A4 A G 0.23 0.10 0.01 4.08E-22 
2 rs6724322 102491614 SLC9A4 T C 0.23 0.10 0.01 4.13E-22 
2 rs4851607 102492064 SLC9A4 T C 0.23 0.10 0.01 4.16E-22 
2 rs10195948 102492168 SLC9A4 C T 0.23 0.10 0.01 4.19E-22 
2 rs4851616 102518294 SLC9A4 T C 0.23 0.10 0.01 6.30E-22 
2 rs6724213 102517651 SLC9A4 C A 0.23 0.10 0.01 6.41E-22 
2 rs4851615 102513431 SLC9A4 T G 0.43 0.09 0.01 8.39E-22 
2 rs6708949 102490397 SLC9A4 C G 0.23 0.10 0.01 9.36E-22 
2 rs9989749 102490074 SLC9A4 A G 0.23 0.10 0.01 9.57E-22 
 15 
2 rs13019784 102489733 SLC9A4 G A 0.23 0.10 0.01 9.84E-22 
2 rs1024798 102508083 SLC9A4 C G 0.23 0.10 0.01 1.14E-21 
2 rs10172553 102519407 SLC9A4 T C 0.43 0.08 0.01 1.54E-21 
2 rs11123935 102506183 SLC9A4 G A 0.23 0.10 0.01 1.64E-21 
2 rs12712155 102494395 SLC9A4 T A 0.23 0.10 0.01 1.71E-21 
2 rs4851609 102495298 SLC9A4 C T 0.23 0.10 0.01 1.72E-21 
2 rs10193407 102505730 SLC9A4 T C 0.23 0.10 0.01 1.73E-21 
2 rs6761291 102521501 SLC9A4 T C 0.43 0.08 0.01 1.75E-21 
2 rs11676371 102496124 SLC9A4 C G 0.23 0.10 0.01 1.75E-21 
2 rs4851608 102492416 SLC9A4 T C 0.43 0.09 0.01 1.79E-21 
2 rs2058656 102503458 SLC9A4 G T 0.43 0.08 0.01 1.80E-21 
2 rs4851612 102504312 SLC9A4 G C 0.43 0.08 0.01 1.80E-21 
2 rs2192758 102498701 SLC9A4 G C 0.23 0.10 0.01 1.81E-21 
2 rs2192757 102498810 SLC9A4 T C 0.23 0.10 0.01 1.84E-21 
2 rs1476999 102498111 SLC9A4 A G 0.43 0.09 0.01 1.86E-21 
2 rs2216000 102499072 SLC9A4 C G 0.43 0.09 0.01 1.90E-21 
2 rs1523204 102502069 SLC9A4 A G 0.43 0.09 0.01 1.94E-21 
2 rs1523203 102502191 SLC9A4 G A 0.23 0.10 0.01 1.99E-21 
2 rs4851611 102502370 SLC9A4 T A 0.23 0.10 0.01 2.02E-21 
2 rs6750971 102505257 SLC9A4 G A 0.23 0.10 0.01 2.04E-21 
2 rs1403551 102502878 SLC9A4 G T 0.23 0.10 0.01 2.04E-21 
2 rs1403550 102502741 SLC9A4 C T 0.23 0.10 0.01 2.04E-21 
2 rs4851613 102504422 SLC9A4 C T 0.23 0.10 0.01 2.12E-21 
2 rs6750851 102505193 SLC9A4 G A 0.23 0.10 0.01 2.14E-21 
2 rs2215998 102532475 SLC9A4 G A 0.43 0.08 0.01 2.95E-21 
2 rs10194822 102531936 SLC9A4 G T 0.43 0.08 0.01 3.05E-21 
2 rs11685483 102525525 SLC9A4 C A 0.23 0.10 0.01 3.18E-21 
2 rs10196579 102536613 SLC9A4 T C 0.43 0.08 0.01 3.48E-21 
2 rs2310295 102537498 SLC9A4 A G 0.43 0.08 0.01 4.21E-21 
2 rs759381 102460755 SLC9A4 T A 0.24 0.10 0.01 4.62E-21 
2 rs6739426 102526875 SLC9A4 G A 0.23 0.10 0.01 4.64E-21 
2 rs2871474 102517873 SLC9A4 A G 0.21 0.11 0.01 5.95E-21 
2 rs4851019 102543997 SLC9A4 A T 0.43 0.08 0.01 7.61E-21 
2 rs10202404 102543846 SLC9A4 T C 0.43 0.08 0.01 7.61E-21 
2 rs11899041 102527485 SLC9A4 A T 0.23 0.10 0.01 7.64E-21 
2 rs9989842 102490065 SLC9A4 G C 0.21 0.11 0.01 1.11E-20 
2 rs6714379 102499742 SLC9A4 G A 0.20 0.11 0.01 1.73E-20 
2 rs7600901 102282003 IL1RL1 A G 0.14 0.13 0.01 2.74E-20 
2 rs12997225 102231180 IL1RL2 A C 0.06 -0.18 0.02 2.82E-20 
2 rs13018912 102230742 IL1RL2 G T 0.06 -0.18 0.02 2.86E-20 
2 rs1303960 102532264 SLC9A4 A G 0.23 0.10 0.01 5.17E-20 
2 rs759382 102460645 SLC9A4 T G 0.23 0.10 0.01 5.35E-20 
2 rs12712157 102531561 SLC9A4 C T 0.23 0.10 0.01 5.59E-20 
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2 rs13019803 102142634 IL1R1 C T 0.12 -0.14 0.02 5.95E-20 
2 rs2005881 102539491 SLC9A4 A G 0.23 0.10 0.01 1.05E-19 
2 rs6761871 102543229 SLC9A4 C A 0.23 0.10 0.01 1.51E-19 
2 rs4851619 102542843 SLC9A4 T C 0.23 0.10 0.01 1.67E-19 
2 rs12993937 102222263 IL1RL2 G T 0.06 -0.18 0.02 3.33E-19 
2 rs6543146 102463127 SLC9A4 G T 0.42 0.08 0.01 8.53E-18 
2 rs12995229 102213339 IL1RL2 A G 0.06 -0.17 0.02 9.24E-18 
2 rs1030026 102464610 SLC9A4 C A 0.42 0.08 0.01 1.27E-17 
2 rs2140316 102465108 SLC9A4 A T 0.42 0.08 0.01 1.94E-17 
2 rs1861245 102333338 IL1RL1 C T 0.39 0.08 0.01 2.94E-17 
2 rs6759588 102406591 IL18RAP A G 0.13 0.12 0.01 3.00E-17 
2 rs13424006 102333668 IL1RL1 T C 0.39 0.08 0.01 3.25E-17 
2 rs6751967 102333845 IL1RL1 T C 0.39 0.08 0.01 3.39E-17 
2 rs6749114 102334019 IL1RL1 A C 0.39 0.08 0.01 3.54E-17 
2 rs4988956 102334439 IL1RL1 G A 0.39 0.08 0.01 3.66E-17 
2 rs4988957 102334507 IL1RL1 T C 0.39 0.08 0.01 3.66E-17 
2 rs10204137 102334644 IL1RL1 A G 0.39 0.08 0.01 3.66E-17 
2 rs4988955 102334360 IL1RL1 A G 0.39 0.08 0.01 3.67E-17 
2 rs4988958 102334717 IL1RL1 T C 0.39 0.08 0.01 3.84E-17 
2 rs10192157 102334788 IL1RL1 C T 0.39 0.08 0.01 4.06E-17 
2 rs1362348 102351056 IL18R1 C G 0.39 0.08 0.01 4.11E-17 
2 rs10206753 102334794 IL1RL1 T C 0.39 0.08 0.01 4.33E-17 
2 rs3755276 102344891 IL18R1 C T 0.39 0.08 0.01 4.88E-17 
2 rs10176664 102342604 IL18R1 G A 0.39 0.08 0.01 5.15E-17 
2 rs7603730 102340803 IL18R1 A C 0.39 0.08 0.01 6.09E-17 
2 rs13017475 102219640 IL1RL2 C T 0.06 -0.17 0.02 7.83E-17 
2 rs4851602 102482737 SLC9A4 A G 0.42 0.08 0.01 8.97E-17 
2 rs13002972 102218293 IL1RL2 G A 0.06 -0.17 0.02 9.30E-17 
2 rs10170583 102341196 IL18R1 G A 0.39 0.08 0.01 1.13E-16 
2 rs12987900 102215780 IL1RL2 G A 0.06 -0.17 0.02 1.30E-16 
2 rs1997502 102210681 IL1RL2 G A 0.34 0.08 0.01 2.92E-16 
2 rs7600961 102401887 IL18RAP G A 0.13 0.11 0.01 3.25E-16 
2 rs11465670 102400872 IL18RAP T C 0.13 0.11 0.01 3.37E-16 
2 rs3771166 102352654 IL18R1 G A 0.38 0.08 0.01 3.43E-16 
2 rs1974675 102352807 IL18R1 G A 0.38 0.08 0.01 3.52E-16 
2 rs1558648 102176600 IL1RL2 T G 0.13 -0.13 0.02 3.94E-16 
2 rs13014084 102221197 IL1RL2 A G 0.07 -0.15 0.02 4.09E-16 
2 rs13033782 102210265 IL1RL2 G A 0.06 -0.16 0.02 5.31E-16 
2 rs11465698 102421009 IL18RAP T C 0.13 0.11 0.01 6.65E-16 
2 rs12992518 102204030 IL1RL2 C T 0.06 -0.16 0.02 7.06E-16 
2 rs6741230 102436063 IL18RAP C T 0.13 0.11 0.01 7.55E-16 
2 rs13028635 102198716 IL1RL2 C T 0.06 -0.16 0.02 7.65E-16 
2 rs13002813 102197712 IL1RL2 T C 0.06 -0.16 0.02 7.74E-16 
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2 rs12989930 102196254 IL1RL2 T C 0.06 -0.16 0.02 7.87E-16 
2 rs10490570 102194171 IL1RL2 C T 0.06 -0.16 0.02 8.15E-16 
2 rs13021607 102191158 IL1RL2 G A 0.06 -0.16 0.02 8.86E-16 
2 rs7605606 102487968 SLC9A4 A G 0.36 0.08 0.01 1.08E-15 
2 rs3917254 102142950 IL1R1 G A 0.11 -0.12 0.02 1.14E-15 
2 rs12987222 102180548 IL1RL2 G T 0.06 -0.16 0.02 1.19E-15 
2 rs6754776 102131210 IL1R1 C G 0.13 -0.11 0.01 2.16E-15 
2 rs2241132 102170467 IL1RL2 C A 0.11 -0.13 0.02 2.68E-15 
2 rs3917291 102148598 IL1R1 G A 0.06 -0.16 0.02 1.20E-14 
2 rs3917314 102157295 IL1R1 A C 0.06 -0.15 0.02 1.98E-14 
2 rs3917320 102159307 IL1R1 A C 0.06 -0.15 0.02 2.13E-14 
2 rs3917328 102160973 IL1R1 C T 0.06 -0.15 0.02 2.21E-14 
2 rs3917325 102160339 IL1R1 T G 0.06 -0.15 0.02 2.21E-14 
2 rs1016160 102611457 SLC9A2 G A 0.16 0.09 0.01 4.68E-14 
2 rs2310187 102116860 IL1R1 G T 0.13 -0.10 0.01 5.61E-14 
2 rs6752379 102113137 IL1R1 G A 0.13 -0.10 0.01 6.58E-14 
2 rs13035227 102130269 IL1R1 T C 0.15 -0.11 0.01 1.72E-13 
2 rs10208542 102098747 IL1R1 G C 0.12 -0.10 0.01 1.80E-13 
2 rs871195 102101269 IL1R1 C A 0.12 -0.10 0.01 2.07E-13 
2 rs13029169 102102173 IL1R1 G A 0.12 -0.10 0.01 2.19E-13 
2 rs13012334 102102452 IL1R1 A G 0.12 -0.10 0.01 2.23E-13 
2 rs7557377 102103020 IL1R1 C T 0.12 -0.10 0.01 2.25E-13 
2 rs12470623 102110447 IL1R1 A T 0.12 -0.10 0.01 2.26E-13 
2 rs6712813 102104458 IL1R1 C T 0.12 -0.10 0.01 2.36E-13 
2 rs6727859 102104596 IL1R1 A G 0.12 -0.10 0.01 2.38E-13 
2 rs6727985 102104707 IL1R1 A G 0.12 -0.10 0.01 2.38E-13 
2 rs2310186 102109612 IL1R1 T G 0.12 -0.10 0.01 2.38E-13 
2 rs1468790 102458873 SLC9A4 C G 0.45 0.07 0.01 6.78E-13 
2 rs1468788 102458945 SLC9A4 T C 0.45 0.07 0.01 6.80E-13 
2 rs1115281 102257539 IL1RL2 G C 0.33 0.07 0.01 6.95E-13 
2 rs10469856 102255261 IL1RL2 T A 0.33 0.07 0.01 8.87E-13 
2 rs3755285 102210452 IL1RL2 T C 0.26 -0.07 0.01 1.20E-12 
2 rs12996377 102196910 IL1RL2 T A 0.13 -0.10 0.01 1.32E-12 
2 rs10200945 102251189 IL1RL2 T A 0.33 0.07 0.01 1.60E-12 
2 rs11123915 102247255 IL1RL2 T G 0.33 0.07 0.01 1.76E-12 
2 rs11692304 102461836 SLC9A4 G A 0.50 -0.06 0.01 2.20E-12 
2 rs17775170 102618359 SLC9A2 G A 0.21 -0.08 0.01 3.50E-12 
2 rs4851610 102501084 SLC9A4 G C 0.17 0.08 0.01 4.23E-12 
2 rs3917296 102151265 IL1R1 A G 0.09 0.12 0.02 7.15E-12 
2 rs11123913 102191911 IL1RL2 T C 0.24 -0.07 0.01 1.07E-11 
2 rs11123912 102182968 IL1RL2 G A 0.24 -0.07 0.01 1.13E-11 
2 rs2302621 102208556 IL1RL2 T G 0.40 0.06 0.01 1.48E-11 
2 rs917994 102203846 IL1RL2 A G 0.40 0.06 0.01 1.52E-11 
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2 rs6743219 102198143 IL1RL2 C T 0.40 0.06 0.01 1.54E-11 
2 rs1922291 102195249 IL1RL2 G A 0.40 0.06 0.01 1.57E-11 
2 rs1922302 102185481 IL1RL2 G T 0.40 0.06 0.01 1.58E-11 
2 rs12474258 102183127 IL1RL2 T C 0.40 0.06 0.01 1.65E-11 
2 rs2302612 102218140 IL1RL2 T C 0.18 -0.08 0.01 2.08E-11 
2 rs6754556 102217356 IL1RL2 A T 0.18 -0.08 0.01 2.22E-11 
2 rs6709635 102216871 IL1RL2 G A 0.18 -0.08 0.01 2.30E-11 
2 rs13007967 102099210 IL1R1 A G 0.14 -0.09 0.01 3.34E-11 
2 rs12712129 102100017 IL1R1 G A 0.14 -0.09 0.01 3.39E-11 
2 rs955754 102215513 IL1RL2 T C 0.18 -0.08 0.01 3.58E-11 
2 rs6758443 102214494 IL1RL2 G T 0.18 -0.08 0.01 5.82E-11 
2 rs11693697 102282094 IL1RL1 T C 0.21 -0.08 0.01 6.81E-11 
2 rs10207579 102469721 SLC9A4 T C 0.48 0.06 0.01 6.87E-11 
2 rs4851604 102485313 SLC9A4 A G 0.48 0.06 0.01 9.85E-11 
2 rs4851606 102487321 SLC9A4 A G 0.30 0.06 0.01 1.10E-10 
2 rs4851605 102487300 SLC9A4 G A 0.30 0.06 0.01 1.11E-10 
2 rs7558013 102359238 IL18R1 G T 0.21 0.07 0.01 2.81E-09 
2 rs10515922 102281086 IL1RL1 A G 0.09 -0.09 0.02 5.12E-09 
2 rs17027173 102423475 IL18RAP G A 0.22 0.07 0.01 6.88E-09 
2 rs6543135 102428838 IL18RAP C T 0.27 0.06 0.01 9.89E-09 
2 rs10167431 102219234 IL1RL2 C T 0.48 0.05 0.01 1.04E-08 
2 rs1558625 102228596 IL1RL2 G A 0.34 0.06 0.01 1.40E-08 
2 rs4851017 102487201 SLC9A4 A C 0.29 0.06 0.01 1.55E-08 
2 rs7567885 102475284 SLC9A4 G T 0.29 0.06 0.01 1.56E-08 
2 rs1403548 102476807 SLC9A4 T C 0.29 0.06 0.01 1.56E-08 
2 rs12712153 102478193 SLC9A4 T C 0.29 0.06 0.01 1.56E-08 
2 rs11687071 102478352 SLC9A4 A G 0.29 0.06 0.01 1.56E-08 
2 rs7566063 102478997 SLC9A4 A C 0.29 0.06 0.01 1.56E-08 
2 rs7591872 102479073 SLC9A4 C G 0.29 0.06 0.01 1.56E-08 
2 rs7591878 102479090 SLC9A4 A G 0.29 0.06 0.01 1.56E-08 
2 rs4851016 102486832 SLC9A4 T C 0.29 0.06 0.01 1.60E-08 
2 rs2075187 102486743 SLC9A4 A G 0.29 0.06 0.01 1.62E-08 
2 rs11465699 102421199 IL18RAP G A 0.04 0.14 0.02 1.64E-08 
2 rs11690932 102485461 SLC9A4 A G 0.29 0.06 0.01 1.73E-08 
2 rs2075190 102484991 SLC9A4 T A 0.29 0.06 0.01 1.76E-08 
2 rs2075191 102484731 SLC9A4 T G 0.29 0.06 0.01 1.77E-08 
2 rs2075192 102484660 SLC9A4 G A 0.29 0.06 0.01 1.77E-08 
2 rs2075193 102484459 SLC9A4 A G 0.29 0.06 0.01 1.78E-08 
2 rs6728288 102483700 SLC9A4 T A 0.29 0.06 0.01 1.80E-08 
2 rs12995030 102482898 SLC9A4 G C 0.29 0.06 0.01 1.81E-08 
2 rs12987295 102482270 SLC9A4 A G 0.29 0.06 0.01 1.82E-08 
2 rs4851012 102482347 SLC9A4 T C 0.29 0.06 0.01 1.83E-08 
2 rs4851600 102482655 SLC9A4 G C 0.29 0.06 0.01 1.83E-08 
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2 rs4851014 102482708 SLC9A4 T C 0.29 0.06 0.01 1.83E-08 
2 rs10175045 102469664 SLC9A4 C T 0.29 0.06 0.01 2.16E-08 
2 rs1523198 102464906 SLC9A4 T C 0.29 0.06 0.01 2.17E-08 
2 rs6725806 102582604 SLC9A2 G T 0.26 0.06 0.01 3.21E-08 
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Supplemental Table 3. Suggestive loci associated with sST2 (P<1 x 10-6) 
 
Chr SNP Position Nearest Location Allele MAF P-value 
   (NCBI 36.3) gene (s)  (major/minor)   
1 rs1775453 195895965 DENND1B intronic T/C 0.26 2.34E-07 
1 rs10923038 88424359 PKN2 intergenic A/C 0.34 4.17E-07 
18 rs206548 10372883 APCDD1 intergenic C/T 0.48 8.57E-07 
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Supplemental Table 4. Association of top 10 sST2 SNPs and clinical phenotypes (p-valuesA) 
 
Trait rs950880 rs13029918 rs1420103 rs1014286 rs17639215 rs12999542 rs13019803 rs1558648 rs2302612 rs11693697 
           
Clinical Disease Phenotypes          
CVD (25) 0.52 0.23 0.39 0.38 0.39 0.35 0.04 0.69 0.11 0.24 
Mortality (26)  0.91 0.36 0.72 0.83 0.78 0.51 0.03 0.003 0.36 0.54 
Heart failure (27) 0.38 0.46 0.35 0.63 0.43 0.33 0.69 0.34 0.71 0.34 
Asthma (28) NA NA NA 0.24 NA NA NA NA 0.02 0.94 
           
Clinical Traits          
Systolic BP (29) 0.50 0.80 0.40 0.43 0.86 0.75 0.81 0.39 0.92 0.76 
Diastolic BP (29) 0.51 0.37 0.69 0.44 0.85 0.87 0.77 0.24 0.65 0.57 
BMI (30)  0.80 0.35 0.87 0.53 0.89 0.33 0.11 0.62 0.13 0.50 
Fasting glucose (31) 0.13 0.29 0.11 0.04 0.28 0.01 0.93 0.27 0.20 0.55 
HOMA-IR (31) 0.80 0.52 0.57 0.39 0.37 0.80 0.35 0.48 0.80 0.79 
HDL (32) 0.40 0.99 0.86 0.85 0.52 0.32 0.50 0.23 0.96 0.24 
LDL (32) 0.25 0.74 0.84 0.51 0.61 0.61 0.74 0.73 0.28 0.30 
Total cholesterol 
(32) 0.41 0.59 0.96 0.38 0.56 0.65 0.80 0.94 0.11 0.84 
Triglycerides (32) 0.30 0.62 0.10 0.22 0.41 0.66 0.46 0.35 0.32 0.37 
           
Biomarker traits          
BNP (FHS) 0.18 0.63 1.00 0.64 0.97 0.67 0.66 0.11 0.58 0.66 
NT-proBNP (FHS) 0.06 0.13 0.31 0.79 0.03 0.03 0.16 0.97 0.11 0.21 
CRP (33) 0.02 0.01 0.0004 0.01 1.00 0.66 0.01 0.003 0.03 0.05 
           
Echocardiographic traits          
LV diast. dim. (34) 0.85 0.31 0.59 0.02 0.16 0.25 0.16 0.35 0.45 0.65 
LV mass (34) 0.32 0.65 0.69 0.02 0.02 0.68 0.16 0.34 0.28 0.61 
LA dimension (34) 0.31 0.68 0.04 0.08 0.71 0.91 0.96 0.84 0.90 0.92 
 
ABonferroni-corrected P-value threshold = 0.005
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Supplemental Table 5. sST2 concentrations according to genotype for missense variants 
 
 Major/minor sST2 concentration, ng/ml (SD) 
Variant Allele Major homozygote Heterozygote Minor homozygote 
rs6749114* (Q501K) A/C 20.9 (8.2) 22.4 (8.2) 24.1 (9.6) 
rs4988956 (A433T) G/A 20.9 (8.2) 22.4 (8.2) 24.1 (9.6) 
rs10204137 (Q501R) A/G 20.9 (8.2) 22.4 (8.2) 24.1 (9.6) 
rs10192157 (T549I) C/T 20.9 (8.2) 22.4 (8.2) 24.1 (9.6) 
rs10206753 (L551S) T/C 20.9 (8.2) 22.4 (8.2) 24.1 (9.6) 
rs1041973 (A78E) C/A 22.6 (8.4) 21.6 (8.6) 20.4 (7.7) 
 
*perfect proxy for nSNP 10192036 in 1000 Genomes Pilot 1 dataset   
 23 
 Supplemental Table 6.  Association of sST2 genetic variants with previously reported immune 
and inflammatory conditions  
rsID sST2 P Previous disease Previous 
disease P 
Reference 
rs1420101 4.33 x 10-92 Eosinophil count 
Asthma 
5.3 x 10-14 
5.5 x 10-12 
Gudbjartsson DF,  
Nat Genet, 2009 (35) 
 
rs13015714 4.47 x 10-33 
 
Celiac disease 4.4 x 10-9 Hunt K,  
Nat Genet, 2008(36) 
 
rs917997 3.36 x 10-31 
 
Crohn's disease 2.2 x 10-6 Wang K, 
Hum Mol Genet, 2010 
(37) 
 
rs917997 3.36 x 10-31 Inflammatory bowel 
disease 
1.9 x 10-8 Zhernakova A,  
Am J Hum Genet, 2008 
(38) 
 
rs917997 3.36 x 10-31 Celiac disease 8.5 x 10-10 Hunt K,  
Nat Genet, 2008 (36) 
 
rs917997 3.36 x 10-31 Type 1 diabetes 8.0 x 10-5 Smyth DJ,  
N Engl J Med, 2008 (39) 
 
rs1035127 5.65 x 10-31 Crohn’s Disease 1.2 x 10-4 Barrett JC, 
Nat Genet, 2008 (40) 
 
rs1974675 3.52 x 10-16 
 
Asthma 5.0 x 10-5 Zhu G,  






Supplemental Figure 1  
 
Quantile-quantile plot of sST2 genome-wide association study 
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Supplemental Figure 2 
 










Regional linkage disequilibrium plot displaying genetic loci within the same region as IL1RL1
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Supplemental Figure 4 
 




Gene expression levels of IL1RL1 and circulating sST2 levels by rs13001325 genotype.  In panel A, there was a 
1.9 fold higher expression level of IL1RL1 in pre-frontal cortex tissue of major homozygotes (CC) compared with 
minor homozygotes (TT) for rs13001325.  Expression levels are expressed in mean log ratio of the intensity 
measurements between IL1RL1 gene expression and reference channels.(42)  In panel B, sST2 concentrations are 
associated with rs13001325 genotype with the same directionality as gene expression.  Standard errors by genotype 
are 0.42 ng/ml (CC), 0.22 (CT), and 0.22 (TT).   
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Supplemental Figure 5 
 
Basal mRNA expression of IL-33, IL-1β , sST2, and ST2L in KU812 cells and stable cells expressing 
wildtype ST2L. mRNA expression in KU812 cells expressing the wildtype ST2L and the uninfected control 
KU812 were analyzed by realtime RT-PCR. Primers targeting the 3’-UTR or coding sequences (CDS) of ST2L 
were used to detect endogenous or exogenous ST2L expression, respectively. 
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Supplemental Figure 6 
 
Expression of ST2 protein in cells expressing IL1RL1 variants.  (A) Membrane and cytosol fractions subtracted 
from whole cell lysates were analyzed by immunoblotting with anti-ST2 mAb (for both ST2L and sST2), anti-His 
(for exogenous ST2L-His), anti-Insulin receptor b (IRb, for quality control of membrane fraction), or anti-tubulin 
(for quality control of cytosol fraction).  Protein levels of sST2 (B) and ST2L (C) were quantified by relative 
intensity.  Data are representative of 2 independent experiments. 
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Supplemental Figure 7 
 
IL1RL1 intracellular missense variants induce sST2 and IL-33 in U937, Jurkat T and A549 cells. (A) U937, 
(B) Jurkat T, and (C) A549 cells (three stable cell lines per group) expressing wild type (WT) and IL1RL1 missense 
variants were cultured in serum free RPMI 1640 medium for 24 h. Media were collected for ELISA analysis of  
sST2 levels. *P <0.05 compare to WT group. Error bars represent mean ± s.e. from two independent experiments. 
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Supplemental Figure 8 
 
IL1RL1 missense variants upregulated both proximal and distal ST2 promoter activities.  KU812 cells (1 x 
106/well) expressing WT or ST2 variants were transfected with (a) proximal ST2 promoter construct (-1745/+200) 
or (b) distal ST2 promoter construct (-697/+741) for 18 h and then medium was changed to serum free RPMI-1640 
and cells were cultured for additional 24 h.  Cell lysates were then analyzed using a luciferase assay. #P<0.05 vs 
WT. Error bars represent mean ± s.e from two independent experiments.   
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Supplemental Figure 9 
 
 
Correlation between sST2 and IL-1β in cells expressing IL1RL1 missense variants. KU812 cells (5x105/well) 
expressing WT or ST2L variants were cultured in serum free RPMI-1640 medium for 24 hours.  Media were then 
collected for ELISA analysis for sST2 and IL-1β. Effect of (A) IL-33 or (B) IL-1β on sST2 expression in cells 
expressing IL1RL1 variants.  Dashed line indicates PBS treated cells as referent group. Data are mean ± s.e. from 




Supplemental Figure 10 
 
IL-33 induced sST2 expression through an ST2-dependent pathway.  KU812 cells (5x105/well, three different 
stable cell lines in each group) expressing WT or IL1RL1 variants were treated with PBS, IL-33, or IL-33 + anti-
ST2, for 24 hours.  Media were then collected for ELISA analysis for sST2.  Error bars represent mean ± s.e from 
two independent experiments. *P<0.05 for IL-33 vs IL33+anti-ST2.  
 
 34 
Supplemental Figure 11 
 
Interaction between IL-33, sST2 and IL-1β . (A) Incubation of anti-IL-1β mAb reduced the basal sST2 expression 
in KU812 cells expressing the IL1RL1 variants. (B) Blocking of IL-33 by addition of sST2 did not affect basal IL-1β 
levels. (C) Basal IL-33 levels were reduced by anti-IL-1β and sST2. (D) Schematic model depicting the interaction 
between IL-33, sST2, and IL-1β. (a) IL-33 itself upregulates sST2, which in turn feeds back to inhibit IL-33 levels. 
(b) IL-33 has limited effect on basal IL-1β expression in these conditions. (c) IL-1β acts as an inducer of IL-33 and 
sST2.  * p<0.05 compare to PBS treated group. Three stable cell lines were analyzed in each group. Error bars 
represent mean ± s.e. from two independent experiments. 
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Supplemental Figure 12  
 
 
IL1RL1 missense variants did not affect STAT3 activation. KU812 cells (5x105/well, three different stable cell 
line in each group) expressing WT or ST2L variants were treated with PBS or IL-33 (20ng/ml) for 30 minutes. 
Phosphor-STAT3 was analyzed using ELISA-based phosphor-protein assay. (a) Basal phosphor-STAT3 level. (b) 








Regulation of the proximal and distal IL1RL1 promoters by IL1RL1 variants. (A) Proximal promoter activity 
and (B) distal promoter activity were analyzed in cells expressing IL1RL1 variants treated with BAY11-7082 (10 
µM) or SR11301 (10 µM). * p<0.05 compare to PBS treated group. Three stable cell lines were analyzed in each 
group. Error bars represent mean ± s.e. from two independent experiments. 
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Supplemental Figure 14 
 
IL1RL1 variants A433T and Q501R interact with the PI3K-p85 subunit, Mal, and MYD88.  Cell lysates from 
HEK293 cells co-expressing the ST2L variants, PI3K-p85-FLAG, Mal-c-myc, and MYD88-HA were 
immunoprecipitated by using anti-ST2L mAb, then immunoblotted by anti-FLAG for PI3K-p85 subunit, anti-c-myc 
for Mal, anti-HA for MYD88, or anti-His for ST2L variant protein.  Precipitates and whole cell lysates were 
analyzed by immunoblot. 
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Supplemental Figure 15 
 
Mal and MYD88 are required for the upregulation of sST2 levels by intracellular IL1RL1 variants.  KU812 
cells expressing IL1RL1 variants were treated with PBS, IL-33, IL-33 plus Mal-siRNA, or IL-33 plus PI3K-p85-
siRNA.  Culture media were collected after 72 hr treatment.  Levels of sST2 were analyzed by ELISA.  Three stable 
cell lines were analyzed in each group.  Error bars represent mean ± s.e. from two independent experiments. *p<0.05 
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